Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.

01:10 EDT 26th October 2014 | BioPortfolio

Summary of "Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity."


RATIONALE:
Smoking rates are up to five times higher in people with schizophrenia than in the general population, placing these individuals at high risk for smoking-related health problems. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is a promising aid for smoking cessation in this population. To maximize treatment efficacy while minimizing risks, it is critical to identify reliable predictors of positive response to varenicline in smokers with schizophrenia.
OBJECTIVES:
Negative symptoms of schizophrenia are related to dysfunctions in the brain reward system, are associated with nicotine dependence, and may be improved by nicotine or nicotinic receptor agonists, suggesting that smoking cessation may be especially difficult for patients with substantial negative symptoms. The purpose of the study was to evaluate negative symptoms as predictors of response to varenicline.
METHODS:
Patients with schizophrenia (N = 53) completed a 12-week smoking cessation trial combining varenicline with cognitive behavioral therapy. Negative symptoms were assessed via the Scale for the Assessment of Negative Symptoms (Andreasen 1983). Outcomes included smoking abstinence as assessed by self-report and expired carbon monoxide. Change in performance on a probabilistic reward task was used as an index of change in reward sensitivity during treatment.
RESULTS:
At week 12, 32 participants met criteria for 14-day point-prevalence abstinence. Patients with lower baseline symptoms of affective flattening (more typical affect) were more likely to achieve smoking abstinence and demonstrated larger increases in reward sensitivity during treatment.
CONCLUSIONS:
These data suggest that affective flattening symptoms in smokers with schizophrenia may predict response to varenicline.

Affiliation

Department of Psychology, Yale University, P.O. Box 208205, New Haven, CT, 06520, USA.

Journal Details

This article was published in the following journal.

Name: Psychopharmacology
ISSN: 1432-2072
Pages:

Links

PubMed Articles [17578 Associated PubMed Articles listed on BioPortfolio]

Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.

Virtually no clinical trials for smoking cessation have been undertaken in bipolar disorder. Varenicline has shown efficacy for smoking cessation, but warnings about neuropsychiatric adverse events ha...

The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement.

Varenicline was developed to aid smoking cessation by reducing smoking reinforcement. The present study tests this reinforcement-reduction hypothesis among smokers preparing to quit.

Promoting smoking cessation among parents: Effects on smoking-related cognitions and smoking initiation in children.

Parental smoking is associated with an increased risk of smoking among youth. Epidemiological research has shown that parental smoking cessation can attenuate this risk. This study examined whether te...

Nasal and systemic inflammatory profile after short term smoking cessation.

Smoking cessation promotes health benefits and, despite cigarette smoking be an important pro inflammatory stimulus, there are few studies concerning the nasal and systemic inflammation; as well as th...

Predictors of Lapse and Relapse to Smoking in Successful Quitters in a Varenicline Post Hoc Analysis in Japanese Smokers.

The efficacy of the smoking-cessation agent varenicline has been reported in Asian smokers; however, few studies have investigated factors that contribute to lapse and relapse.

Clinical Trials [2730 Associated Clinical Trials listed on BioPortfolio]

Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia

The purpose of this proposed pilot study is to examine the use of varenicline in people with schizophrenia to specifically assess tolerability and efficacy for smoking cessation. Specifica...

Varenicline and Smoking Cessation in Schizophrenia

There is a strong association between smoking and schizophrenia with prevalence rates ranging from 74% to 90%, versus a national average of 30% in nonschizophrenic individuals. A number of...

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

The purpose of this study is to examine how smoking cessation medications (varenicline, bupropion) affect the ability to resist smoking and also subsequent ad-lib smoking in non-treatment ...

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

The purpose of this study is to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix ™, is an FDA-approved medication that has been shown to hel...

Long-term Varenicline Treatment for Smoking Cessation

This is a clinical study of the efficacy and safety of up to 52 weeks of varenicline therapy in conjunction with individual counseling for smoking cessation. Adult volunteers in generally...

Medical and Biotech [MESH] Definitions

Discontinuation of the habit of smoking, the inhaling and exhaling of tobacco smoke.

Motivational state produced by inconsistencies between simultaneously held cognitions or between a cognition and behavior; e.g., smoking enjoyment and believing smoking is harmful are dissonant.

Cessation of the habit of using tobacco products for smoking or chewing, including the use of snuff.

A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment.

An alkaloid that has actions similar to NICOTINE on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Psychiatry
Latest News Clinical Trials Research Drugs Reports Corporate
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Advertisement